Evidence map›Paper›PMID 37407456›Full record

ArticleInternal medicine (Tokyo, Japan)2024

High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation.

Yasuhiro Uchida, Daisuke Koyama, Kazuya Manabe, Kengo Suzuki, Naomi Asano, Mamiko Endo, Masahiko Fukatsu, Takahiro Sano, Kiyohito Hayashi, Motoki Takano and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Yasuhiro UchidaDepartment of Hematology, Fukushima Medical University, Japan.
Daisuke KoyamaDepartment of Hematology, Fukushima Medical University, Japan.
Kazuya ManabeDepartment of Hematology, Fukushima Medical University, Japan.
Kengo SuzukiDepartment of Hematology, Fukushima Medical University, Japan.
Naomi AsanoDepartment of Hematology, Fukushima Medical University, Japan.
Mamiko EndoDepartment of Hematology, Fukushima Medical University, Japan.
Masahiko FukatsuDepartment of Hematology, Fukushima Medical University, Japan.
Takahiro SanoDepartment of Hematology, Fukushima Medical University, Japan.
Kiyohito HayashiDepartment of Hematology, Fukushima Medical University, Japan.
Motoki TakanoDepartment of Hematology, Fukushima Medical University, Japan.
Hiroshi TakahashiDepartment of Hematology, Fukushima Medical University, Japan.
Satoshi KimuraDepartment of Hematology, Fukushima Medical University, Japan.
Takayuki IkezoeDepartment of Hematology, Fukushima Medical University, Japan.
Fukushima Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by the BCR::ABL1 tyrosine kinase. Tyrosine kinase inhibitors (TKIs) have been established as standard therapies for CML. However, some CML patients experience TKI intolerance. Asciminib was approved for CML patients either intolerant or refractory to TKI therapy. We herein report a 63-year-old CML patient who underwent renal transplantation and exhibited TKI intolerance. He was switched to asciminib, which achieved a deep molecular response without exacerbation of the renal function. Our experience revealed that asciminib is effective and safe for CML patients complicated with chronic kidney disease.

Indexed as

Kidney TransplantationLeukemia, Myelogenous, Chronic, BCR-ABL PositivePyrazolesRenal Insufficiency, ChronicFusion Proteins, bcr-ablHumansMaleMiddle AgedNiacinamideProtein Kinase InhibitorsasciminibFusion Proteins, bcr-ablNiacinamideProtein Kinase InhibitorsPyrazolesBCR::ABL1, asciminibchronic kidney diseasechronic myeloid leukemiarenal transplantationtyrosine kinase inhibitor

Identifiers

PMID37407456
PMCPMC10982009
OpenAlexW4383112787

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.